This is a basic question and one that governs what constitutes the risk assessment process and what types of data are used. In a recent document entitled 'An examination of EPA risk assessment principles and practices', a Staff Paper prepared for the US Environmental Protection Agency (EPA) by members of the Risk Assessment Task Force (EPA/ 100/B/001) March 2004, the purpose of a risk assessment was defined.
Of particular interest to BELLE is the conclusion that effects that could be beneficial may not be mentioned in the risk assessment process. As the BELLE readership is well aware, BELLE has devoted considerable effort to clarifying the nature of the dose response in the low dose zone. These efforts have revealed that the hormetic dose response is common in the toxicological literature when studies are designed to assess below the no observed adverse effect level (NOAEL) responses. Many of these studies indicate that below traditional NOAEL doses reduce background disease incidence, yielding what many would call a beneficial effect. In fact, a number of recently published studies indicate that the hormetic dose response, when properly studied, is more common than other dose response models, such as the threshold model.1'2 Thus, it is believed that the statement of the EPA Staff Paper needs to be explored, discussed and evaluated by risk assessment scientists outside the agency.
Consequently, I invited a number of recognized experts in the field of risk assessment, who are independent of EPA, for their evaluation of what EPA considers to be the 'purpose of a risk assessment'. The appendix provides the EPA statement to which the experts were invited to respond. These expert responses comprise the remainder of this issue.
